References
- Liu J M, Bignon J, Ilic V, Briscoe C, Lallemand J Y, Riches A, et al. Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development. Leuk Lymphoma 2006; 47: 1915–1920
- Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–936
- Sellke F W, Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs 1999; 58: 391–396
- Sun Y, Weber K T. RAS and connective tissue in the heart. Int J Biochem Cell Biol 2003; 35: 919–931
- Yang F, Yang X P, Liu Y H, Xu J, Cingolani O, Rhaleb N E, Carretero O A. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43: 229–236
- Wang D, Carretero O A, Yang X Y, Rhaleb N E, Liu Y H, Liao T D, Yang X P. yl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H2099–H2105
- Liu J M, Lawrence F, Kovacevic M, et al. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 2003; 101: 3014–3020
- Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D, Frindel E. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 1993; 7: 808–812
- Liozon E, Volkov L, Comte L, et al. AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia. Br J Haematol 1995; 89: 917–920
- Kusinski M, Wdzieczak-Bakala J, Liu J M, Bignon J, Kuzdak K. AcSDKP: a new potential marker of malignancy of the thyroid gland. Langenbeck's Arch Surg 2006; 391: 9–12
- Cha H J, Jeong M J, Kleinman H K. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003; 95: 1674–1680